Botulinum Toxin A (Dysport®)In Dystonias and Focal Spasticity

被引：0
作者：
Susan J. Keam
Victoria J. Muir
Emma D. Deeks
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Cerebral Palsy; Dystonia; Botulinum Toxin; Cervical Dystonia; Blepharospasm;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Dysport®, a formulation of botulinum toxin A, blocks acetylcholine release at neuromuscular junctions causing denervation and temporary muscle paralysis. It is used to treat several medical conditions, including dystonias and focal spasticity.
引用
收藏
页码：1043 / 1058
页数：15
相关论文
共 108 条
[1]  
Velickovic M(2000)A prevalence study of primary dystonia in eight European countries J Neurol 247 787-92
[2]  
Benabou R(2001)Cervical dystonia pathophysiology and treatment options Drugs 61 1921-43
[3]  
Brin MF(2004)Primary blepharospasm: diagnosis and management Drugs 64 237-44
[4]  
Defazio G(2006)Botulinum toxin treatment of adult spasticity: a benefit-risk assessment Drug Saf 29 31-48
[5]  
Livrea P(2009)European consensus table on the use of botulinum toxin type A in adult spasticity J Rehabil Med 41 13-25
[6]  
Sheean G(2010)The updated European Consensus 2009 on the use of botulinum toxin for children with cerebral palsy Eur J Paediatr Neurol 14 45-66
[7]  
Wissel J(2003)Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin Paediatr Drugs 5 11-23
[8]  
Ward AB(2004)Pharmacology and clinical applications of botulinum toxins A and B Int Ophthalmol Clin 44 147-63
[9]  
Erztgaard P(2000)Neurotoxins affecting neuroexocytosis Physiol Rev 80 717-66
[10]  
Heinen F(2005)Pharmacology and immunology of botulinum neurotoxins Int Ophthalmol Clin 45 25-37
12345678910